Table 1 (Abstract 38). Baseline parameters at therapy start 1^st biologic/ JAKI

Age at disease onset, years; mean (±SD)

6.7(±4.6)

Age at disease onset, years; median (IQR1-IQR3)

5.7(2.4–10.7)

Disease duration at baseline, years; mean (±SD)

4.7(±4.0)

Disease duration at baseline, years; median (IQR1-IQR3)

3.5(1.4–7.0)

Age at therapy start, years; mean (±SD)

11.4(±4.4)

Age at therapy start, years; median (IQR1-IQR3)

11.9(8.2–14.9)

ANA-positive n (%)

1557(60.3)

Uveitis n (%)

351(13.6%)

Disease activity

 Physician global assessment disease activity (scale 0–100); median (IQR1-IQR3)

49.8(±26.4)

Patient global assessment disease activity (scale 0–100); median (IQR1-IQR3)

39.8(±27.4)

Active uveits n (%)

182(7.1%)

Active joint count; mean (±SD)

6.9(±7.9)

Active joint count ;median (IQR1-IQR3)

4.0(2.0–9.0)

CHAQ; mean (±SD)

0.6(±0.6)

JADAS10; mean (±SD)

14.9(±7.5)

Therapy at baseline

Steroids n (%)

737(28.6)

Methotrexate n (%)

1833(71.0)